Oracle has released version 27 of the Java programming language and virtual machine. As the second non-LTS release since JDK 25, the final feature set includes nine JEPs, five of which are still ...

Editor’s note, June 30: We removed Sora by OpenAI from this list because it is no longer generally available. OpenAI announced on March 24 that it was discontinuing Sora. It was previously selected as ...

Use them to jump-start lessons, build rubrics, anticipate student questions, differentiate assignments, and more.

Test yourself on topical news trivia, pop culture and general knowledge every Thursday. How will you fare? Every now and then the Thursday quiz gets involved in a flap, as it did last week with “birb” ...

If you are a shareholder who suffered a loss, click here to participate. CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to ...

In January, Meta CEO Mark Zuckerberg and his top lieutenants gathered for their annual leadership retreat at his Hawaii compound. There they hatched a radical plan to reimagine work at the ...

LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Replimune Group, Inc. (REPL) have opportunity to lead the securities fraud ...

Find out how closely you’ve been paying attention to the latest news and other global events by putting your knowledge to the test with our Quiz of The Week. Join more than 350,000 subscribers and ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Replimune Group, Inc. (“Replimune” or the ...

The use of AI systems to create viruses opens up new possibilities for combating bacterial resistance. It also raises concerns about the pace at which technology is outstripping regulation. For ...

FDA advisory panel votes 10-3 that RP1 trial data show patient benefit Replimune seeks accelerated approval for RP1 with Opdivo in refractory or advanced melanoma FDA decision on RP1 is expected by ...